Sepracor to cut sales force jobs

Share this article:

Sepracor will eliminate 300 sales force positions as part of a cost cutting plan to reduce expenses by $90 million-$100 million for 2008.

“We have examined our sales organization in depth,” Adrian Adams, Sepracor's CEO said in a telephone conference with analysts today. “We believe we have an opportunity to significantly raise the performance level so that we can see a positive impact in 2008. We believe that this is an example where we'll be able to do more with less.”

Meanwhile, Sepracor's third quarter profits fell 33% driven by declining revenue from asthma drug Xopenex.

Sales of Xopenex declined for the second straight quarter since Medicare cut reimbursement rates for the drug.

Sales of sleeping pill Lunesta, Sepracor's top-selling product, were up 14% during the quarter.

For more details on Sepracor's third quarter earnings, click here.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.